NDA

NDA. A New Drug Application, Product License Application or the equivalent, which is filed with the United States Food and Drug Administration (or any successor agency) seeking approval to market and sell a Product in the Field in the United States, as well as any corresponding applications or approvals for the Product in the Field in Canada.

NDA. Means ViroPharma's New Drug Application Number 50-606 for the Product, as such application type is defined in the United States Federal Food, Drug and Cosmetic Act, and applicable regulations promulgated thereunder, as amended from time to time.

NDA. Means that certain Mutual Non-Disclosure Agreement between the parties dated as of November 30, 2006.

NDA. Means that certain non-disclosure agreement between CHI and Distributor dated as of September 5, 2008.

NDA. Means a new drug application filed with the FDA to obtain marketing approval for Product in the United States.

NDA. Means a New Drug Application under the Act in the United States.

NDA. Means a new drug application or supplemental new drug application or any amendments thereto submitted to the FDA for marketing authorization of the Product in the United States, or any equivalent application in Japan.

NDA. The new drug application related to each Product, submitted to the FDA pursuant to provisions of the Act and applicable regulations related thereto.

NDA. The "NDA"

NDA. Means a New Drug Application, as defined in the United States Federal Food, Drug, and Cosmetic Act, as amended and regulations promulgated thereunder, or any successor application or procedure to market a Product or Non-Exclusive Product.